Department of Physical Education and Sport Sciences, Faculty of Literature and Human Sciences, Lorestan University, Khoramabad, Iran.
Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
J Med Virol. 2023 Jul;95(7):e28909. doi: 10.1002/jmv.28909.
The association between SARS-CoV-2 infection with increased risk for new-onset neurodegenerative diseases remains unclear. Therefore, this meta-analysis aims to elucidate whether new-onset neurodegenerative diseases are long-term sequelae of SARS-CoV-2 infection. PubMed/MEDLINE, CENTRAL, and EMBASE were systematically searched for articles published up to January 10, 2023. A systematic review and meta-analysis were performed to calculate the pooled effect size, expressed as hazard ratios (HR) with corresponding 95% confidence interval (CI) of each outcome. Twelve studies involving 33 146 809 individuals (2 688 417 post-COVID-19 cases and 30 458 392 controls) were included in the present meta-analysis. The pooled analyses compared with control groups showed a significant association between SARS-CoV-2 infection and increased risk for new-onset Alzheimer's disease (HR = 1.50, 95% CI 1.22-1.85, I = 97%), dementia (HR = 1.66, 95% CI 1.42-1.94, I = 91%), and Parkinson's disease (HR = 1.44, 95% CI 1.06-1.95, I = 86%) among COVID-19 survivors. SARS-CoV-2 infection may be associated with a higher risk for new-onset neurodegenerative diseases in recovered COVID-19 patients. Future studies are warranted to determine the biological mechanisms underlying the neurodegenerative consequences of COVID-19 as long-term sequelae of SARS-CoV-2 infection.
SARS-CoV-2 感染与新发神经退行性疾病风险增加之间的关系尚不清楚。因此，本荟萃分析旨在阐明新发神经退行性疾病是否是 SARS-CoV-2 感染的长期后果。我们系统地检索了截至 2023 年 1 月 10 日发表的 PubMed/MEDLINE、CENTRAL 和 EMBASE 中的文章。进行了系统评价和荟萃分析，以计算汇总效应大小，用每个结局的风险比 (HR) 及其相应的 95%置信区间 (CI) 表示。本荟萃分析纳入了 12 项研究，涉及 33146809 人（2688417 例 COVID-19 后病例和 30458392 例对照）。与对照组相比的汇总分析显示，SARS-CoV-2 感染与新发阿尔茨海默病（HR=1.50，95%CI 1.22-1.85，I²=97%）、痴呆（HR=1.66，95%CI 1.42-1.94，I²=91%）和帕金森病（HR=1.44，95%CI 1.06-1.95，I²=86%）风险增加之间存在显著关联。SARS-CoV-2 感染可能与 COVID-19 幸存者新发神经退行性疾病风险增加有关。需要进一步的研究来确定 COVID-19 作为 SARS-CoV-2 感染的长期后果导致神经退行性后果的生物学机制。
